News - Appointments

Gary Phillips, an experienced pharma executive and practicing physician, has joined Nanobiotix SA as chairman of the company’s supervisory board. In this role, he will help guide the registration of the company’s product for head and neck cancer.

Nucleome Therapeutics Ltd has appointed the investment professional Jonathan Hepple to its board as a non-executive director.

Tom Graney, an experienced finance executive, has been promoted to the position of chief executive officer of Oxurion NV from chief financial officer, succeeding Patrik De Haes who will move onto the board of directors as non-executive chairman.

The Association of the British Pharmaceutical Industry has appointed Ben Osborn as its new president, succeeding Hasseb Ahmad.

The British biotechnology company Engitix Therapeutics Ltd has announced the appointment of Mike Burbridge as vice president, oncology and immuno-oncology.

Glen Clack has joined Evgen Pharma Plc, a UK drug development company, as chief medical officer.

Helsinn Group SA, a Swiss pharmaceutical group that specialises in products for cancer and rare diseases, has announced the appointment of Mary Lynne Hedley to its board of directors.

The French contract research organisation NovAliX SAS has appointed Jerome Guillemont as its new head of drug discovery.

Augustine Therapeutics, a Belgian biotech, has appointed Sylvain Celanire as chief executive to lead the development of new medicines for neurodegenerative diseases.

iTeos Therapeutics Inc has appointed two experienced executives to its board of directors as it advances clinical-stage products for cancer.